Navigation Links
The Leukemia & Lymphoma Society Co-Pay Assistance Fund Surpasses $200 Million

WHITE PLAINS, N.Y., Aug. 21, 2013 /PRNewswire/ -- The Leukemia & Lymphoma Society (LLS) is proud to announce that it has raised more than $200 million in funding for its Co-Pay Assistance Program since its inception in 2007.

The program provides support for prescription drug co-pays and health insurance premiums for blood cancer patients who meet certain income requirements. Patients with private insurance, Medicare beneficiaries under Medicare Part B and/or Medicare Plan D, Medicare Supplementary Health Insurance and Medicare Advantage are eligible.

To date, LLS has helped approximately 36,000 patients through the co-pay program.

"Receiving a diagnosis of a blood cancer can be overwhelming for a patient, and such devastating news can be compounded by an inability to afford the treatments," said John Walter, LLS president and CEO. "LLS's Co-Pay Assistance Program helps alleviate this burden for eligible patients and their families. LLS exists, not only to find cures, but also to ensure access to the best available therapies for all blood cancer patients, and helping patients afford their treatments is a critical part of our mission."

Patients, caregivers, pharmacies and healthcare providers can easily submit online co-pay applications with a quick registration process, day or night. Doctors, treatment providers or pharmacies can apply for the program on behalf of their patients.

Visit or call 877-LLS-COPAY to learn more about the program and which blood cancers are currently covered.

About The Leukemia & Lymphoma Society
The Leukemia & Lymphoma Society ® (LLS) is the world's largest voluntary health agency dedicated to blood cancer. The LLS mission: Cure leukemia, lymphoma, Hodgkin's disease and myeloma, and improve the quality of life of patients and their families. LLS funds lifesaving blood cancer research around the world and provides free information and support services.  

Founded in 1949 and headquartered in White Plains, NY, LLS has chapters throughout the United States and Canada. To learn more, visit  Patients should contact the Information Resource Center at (800) 955-4572, Monday through Friday, 9 a.m. to 6 p.m. ET.

Contact: Andrea Greif
(914) 821-8958, (914) 772-3027 (cell)


SOURCE The Leukemia & Lymphoma Society
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Ibrutinib Study Results in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia Published in The New England Journal of Medicine
2. Celebrating 25 Years and Counting: Leukemia and Lymphoma Societys "Team In Training" Goes the Distance and Beyond for Blood Cancer Patients
3. AbbVie Presents Preliminary Results from Phase I Study of Investigational Oncology Compound ABT-199/GDC-0199 in Patients with High-Risk Chronic Lymphocytic Leukemia (CLL) at European Hematology Association Annual Meeting
4. The Leukemia & Lymphoma Society and Dana-Farber Cancer Institute to Bring Clinical Trials to Local Communities
5. The Leukemia & Lymphoma Society Applauds FDAs Approval of Lenalidomide for Patients with Relapsed or Refractory Mantle Cell Lymphoma
6. The Leukemia & Lymphoma Society, Valor Biotherapeutics and ImmunGene Create Partnership to Advance Novel Therapy for Non-Hodgkin Lymphoma Patients
7. Leading Leukemia Experts: High Leukemia Treatment Costs May Be Harming Patients
8. Tosedostat OPAL Study in Acute Myeloid Leukemia Published in Lancet Oncology
9. Launch Of Premium-priced, Novel Targeted Therapies Will Drive Growth In The Acute Leukemia Markets Beginning In 2015
10. The Leukemia & Lymphoma Society and Avella Specialty Pharmacy to Present Free Event on Oral Chemotherapy Drugs
11. Ambit and Astellas Announce Presentation of Results from Phase 2 ACE Study of Quizartinib in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML) at the 54th Annual Meeting of the American Society of Hematology
Post Your Comments:
(Date:6/23/2016)... 23, 2016 Capricor Therapeutics, ... a biotechnology company focused on the discovery, development ... patient enrollment in its ongoing randomized HOPE-Duchenne clinical ... 50% of its 24-patient target. Capricor expects the ... quarter of 2016, and to report top line ...
(Date:6/23/2016)... -- , , , WHEN: , ... , , , LOCATION: , , , Online, with free ... EXPERT PANELISTS:  , , , Frost & Sullivan,s Global Vice President ... Industry Analyst, Divyaa Ravishankar and Unmesh Lal, Program Manager , ... is witnessing an exceptional era. Several new demand spaces, such as ...
(Date:6/23/2016)... , June 23, 2016 ... Oticon , industry leaders in advanced ... launch of Oticon Opn ™, the world,s first ... of possibilities for IoT devices.      (Photo: ... Oticon introduces a number of ,world firsts,: ...
Breaking Medicine Technology:
(Date:6/25/2016)... , ... June 25, 2016 , ... ... and non-athletes recover from injury. Recently, he has implemented orthobiologic procedures as a ... area —Johnson is one of the first doctors to perform the treatment. Orthobiologics ...
(Date:6/25/2016)... ... 2016 , ... Conventional wisdom preaches the benefits of moderation, whether it’s a ... the bar too high can result in disappointment, perhaps even self-loathing. However, those who ... , Research from reveals that behind the tendency to set ...
(Date:6/24/2016)... Michigan (PRWEB) , ... June 24, 2016 , ... Those ... deal with these feelings, many turn to unhealthy avenues, such as drug or alcohol ... of Marne, Michigan, has released tools for healthy coping following a traumatic event. , ...
(Date:6/24/2016)... ... , ... Marcy was in a crisis. Her son James, eight, was out of control. Prone ... physically. , “When something upset him, he couldn’t control his emotions,” remembers Marcy. “If ... at my other children and say he was going to kill them. If we ...
(Date:6/24/2016)... , ... June 24, 2016 , ... Global law firm ... 2016 Legal Elite. The attorneys chosen by their peers for this recognition are considered ... Seven Greenberg Traurig Shareholders received special honors as members of this year’s Legal Elite ...
Breaking Medicine News(10 mins):